Thursday, April 7, 2011

Gilead boosts HIV drug prices

Dominant HIV drug maker Gilead Sciences Inc. increased the prices of many of its best-selling products this month, according to Dow Jones.
The Foster City-based company (NASDAQ: GILD) boosted the price of Atripla, its best selling HIV antiretroviral drug, by 5.1 percent, the news agency reported. Atripla registered 2010 sales of $1.9 billion, or nearly a quarter of Gilead’s total product sales of $7.39 billion last year.

No comments:

Post a Comment